Skip to main content
Premium Trial:

Request an Annual Quote

Waters Posts 3 Percent Revenue Decline for Q3, but Beats Estimates

NEW YORK (GenomeWeb News) – Waters today reported a 3 percent decline in its third quarter revenues year over year, but the firm said that it sees a stabilization in its end markets after a difficult first half of the year.

The Milford, Mass.-based firm reported total revenues of $374 million for the three-month period ended Oct. 3, down from $386.3 million for Q3 2008. The firm said that 1 percent of that decline was due to adverse foreign currency translation.

Though its total revenues were down year over year, it beat analysts' consensus estimate of $363.5 million. It also improved upon results in the first half of the year, during which Waters' revenues were down 5 percent in Q2 and 6 percent in Q1 compared to the previous year's figures.

"Business trends in the third quarter suggest a stabilization of demand by our major end markets," Waters Chairman, President, and CEO Douglas Berthiaume said in a statement. "Customer interest in our new products is encouraging and indicates that research-related spending may benefit our future results."

Waters' net income for the quarter increased 6 percent to $75.9 million, or $.79 per share, from $71.5 million, or $.71 per share. Analysts, on average, had expected, EPS of $.77.

The firm's R&D spending declined slightly to $19.3 million from $19.9 million, while its SG&A spending dropped 4 percent to $102.7 million from $107.5 million. Its net income also was helped by a lower provision for income taxes, which was $18.1 million for the most recent quarter compared to $22 million the year before.

Waters finished the quarter with $578.1 million in cash, cash equivalents, and short-term investments.

In early trade on the New York Stock Exchange, Waters' shares were up 3 percent at $57.84.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.